A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Brexpiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Registrational
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 27 Aug 2023 This trial has been completed in Poland, according to the European Clinical Trials Database record.
- 23 Apr 2023 This trial has been Completed in Hungary, according to European Clinical Trials Database record.
- 14 Apr 2023 Status changed from recruiting to active, no longer recruiting.